PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
R&D reduction while AVXL shows 6.42% growth. Joel Greenblatt would examine competitive risk.
-21.01%
G&A reduction while AVXL shows 17.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.76%
Operating expenses reduction while AVXL shows 9.01% growth. Joel Greenblatt would examine advantage.
-10.76%
Total costs reduction while AVXL shows 9.01% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
0.96%
D&A growth less than half of AVXL's 4.52%. David Dodd would verify if efficiency is sustainable.
10.97%
EBITDA change of 10.97% while AVXL is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Operating income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
104.37%
Other expenses growth above 1.5x AVXL's 21.08%. Michael Burry would check for concerning trends.
11.35%
Pre-tax income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
305.13%
Tax expense growth 50-75% of AVXL's 451.20%. Bruce Berkowitz would examine efficiency.
11.35%
Net income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
31.03%
EPS growth while AVXL declines. John Neff would investigate advantages.
31.72%
Diluted EPS growth while AVXL declines. John Neff would investigate advantages.
29.31%
Share count reduction below 50% of AVXL's 1.74%. Michael Burry would check for concerns.
29.44%
Diluted share reduction below 50% of AVXL's 1.74%. Michael Burry would check for concerns.